270,000 Shares in Qiagen N.V. $QGEN Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale bought a new stake in Qiagen N.V. (NYSE:QGEN) during the 1st quarter, HoldingsChannel reports. The firm bought 270,000 shares of the company’s stock, valued at approximately $10,811,000.

Other institutional investors have also bought and sold shares of the company. Boston Partners bought a new position in shares of Qiagen in the 3rd quarter worth about $179,450,000. Norges Bank acquired a new position in shares of Qiagen in the 4th quarter valued at about $166,500,000. Dimensional Fund Advisors LP bought a new stake in shares of Qiagen during the 3rd quarter valued at about $58,079,000. Price T Rowe Associates Inc. MD boosted its position in shares of Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Qiagen by 9.7% during the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after purchasing an additional 697,342 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of Qiagen stock opened at $41.19 on Monday. The business has a 50-day simple moving average of $37.34 and a 200 day simple moving average of $42.33. Qiagen N.V. has a one year low of $32.53 and a one year high of $57.81. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. The firm has a market capitalization of $8.49 billion, a price-to-earnings ratio of 21.51, a PEG ratio of 4.11 and a beta of 0.64.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.54. The business had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter in the prior year, the company earned $0.56 earnings per share. On average, research analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The company also recently announced an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were given a dividend of $0.35 per share. The ex-dividend date of this dividend was Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. Qiagen’s payout ratio is currently 18.32%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. TD Cowen reiterated a “hold” rating on shares of Qiagen in a report on Wednesday. Robert W. Baird set a $43.00 price target on Qiagen and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Barclays set a $38.00 price target on Qiagen and gave the stock an “equal weight” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price objective on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. Finally, Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $43.34.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.